There is no central office performing technology assessment at the central level. An office that performed this function in an advisory capacity was abolished in the 1990s. The Federal Government through the Agency for Healthcare Research and Quality reviews and rates clinical preventive services and those services rated A or B must be covered without cost-sharing byall private plans—fully insured and self-insured plans in the individual, small group, and large group markets, except those that maintain “grandfathered” status. In the absence of a governmental HTA body in the U.S., the Institute for Clinical and Economic Review (ICER) is playing an increasing role in evaluating new therapies. ICER is an independent, nonprofit research organization that evaluates the clinical and economic value of prescription drugs, medical tests, and other healthcare delivery innovations. ICER’s profile was elevated in 2015 with their evaluation of hepatitis C. For additional detail, see: https://healthpolicy.usc.edu/wp-content/uploads/2020/02/Health-Technology-Assessment-for-the-U.S.-Healthcare-System_Background-Paper.pdf to 4 times annually at public meetings